SB1578, a novel inhibitor of JAK2, FLT3, and c-Fms for the treatment of rheumatoid arthritis

Journal of Immunology

Volumn 189, Issue 8, 2012, Pages 4123-4134

  Madan, Babita ^a   Goh, Kee Chuan ^a   Hart, Stefan ^a   William, Anthony D ^a   Jayaraman, Ramesh ^a   Ethirajulu, Kantharaj ^a   Dymock, Brian W ^a   Wood, Jeanette M ^a  

^a S BIO Pte Ltd   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

C FMS KINASE; COLLAGEN ANTIBODY; COLLAGEN TYPE 2; DEXAMETHASONE; FLT3 LIGAND; FREUND ADJUVANT; IMMUNOGLOBULIN G ANTIBODY; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 6; JANUS KINASE 2; JANUS KINASE 2 INHIBITOR; KERATINOCYTE DERIVED CHEMOKINE; METHOTREXATE; SB 1578; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG;

ADJUVANT ARTHRITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTHRITIS; ARTICLE; AUTOPHOSPHORYLATION; BONE ATROPHY; CARTILAGE DEGENERATION; CD4+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL INFILTRATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SELECTIVITY; ENZYME PHOSPHORYLATION; EXTRAMEDULLARY HEMATOPOIESIS; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; MACROPHAGE; MALE; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RAT; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SPLENOMEGALY; SYNOVITIS; TH1 CELL;

ANIMALS; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; DISEASE MODELS, ANIMAL; FMS-LIKE TYROSINE KINASE 3; HETEROCYCLIC COMPOUNDS WITH 4 OR MORE RINGS; JANUS KINASE 2; MALE; MICE; MICE, INBRED C57BL; RATS; RATS, INBRED LEW; RECEPTOR, MACROPHAGE COLONY-STIMULATING FACTOR;

EID: 84867304948     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1200675     Document Type: Article

References (54)

1. Gabriel, S. E. 2001. The epidemiology of rheumatoid arthritis. Rheum. Dis. Clin. North Am. 27: 269-281. (Pubitemid 32488705)
2. Walsh, N. C., and E. M. Gravallese. 2010. Bone remodeling in rheumatic disease: a question of balance. Immunol. Rev. 233: 301-312.
3. Choy, E. H., and G. S. Panayi. 2001. Cytokine pathways and joint inflammation in rheumatoid arthritis. N. Engl. J. Med. 344: 907-916. (Pubitemid 32224400)
4. Khan, S., J. D. Greenberg, and N. Bhardwaj. 2009. Dendritic cells as targets for therapy in rheumatoid arthritis. Nat Rev Rheumatol 5: 566-571.
5. Asquith, D. L., and I. B. McInnes. 2007. Emerging cytokine targets in rheumatoid arthritis. Curr. Opin. Rheumatol. 19: 246-251. (Pubitemid 46597461)
6. Stolina, M., B. Bolon, D. Dwyer, S. Middleton, D. Duryea, P. J. Kostenuik, U. Feige, and D. J. Zack. 2008. The evolving systemic and local biomarker milieu at different stages of disease progression in rat collagen-induced arthritis. Biomarkers 13: 692-712.
7. Feldmann, M., F. M. Brennan, and R. N. Maini. 1996. Role of cytokines in rheumatoid arthritis. Annu. Rev. Immunol. 14: 397-440. (Pubitemid 26130190)
8. Woodrick, R., and E. M. Ruderman. 2010. Anti-interleukin-6 therapy in rheumatoid arthritis. Bull. NYU Hosp. Jt. Dis. 68: 211-217.
9. Moreland, L. W. 1999. Inhibitors of tumor necrosis factor for rheumatoid arthritis. J. Rheumatol. Suppl. 57: 7-15. (Pubitemid 29210244)
10. Elliott, M. J., R. N. Maini, M. Feldmann, J. R. Kalden, C. Antoni, J. S. Smolen, B. Leeb, F. C. Breedveld, J. D. Macfarlane, H. Bijl, et al. 1994. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 344: 1105-1110. (Pubitemid 24317629)
11. Bresnihan, B., J. M. Alvaro-Gracia, M. Cobby, M. Doherty, Z. Domljan, P. Emery, G. Nuki, K. Pavelka, R. Rau, B. Rozman, et al. 1998. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum. 41: 2196-2204. (Pubitemid 29009378)
12. Leffers, H. C., M. Ostergaard, B. Glintborg, N. S. Krogh, H. Foged, U. Tarp, T. Lorenzen, A. Hansen, M. S. Hansen, M. S. Jacobsen, et al; all departments of rheumatology in Denmark. 2011. Efficacy of abatacept and tocilizumab in patients with rheumatoid arthritis treated in clinical practice: results from the nationwide Danish DANBIO registry. Ann. Rheum. Dis. 70: 1216-1222.
13. Khraishi, M. 2009. Comparative overview of safety of the biologics in rheumatoid arthritis. J. Rheumatol. Suppl. 82: 25-32.
14. Bingham, C. O., III 2008. Emerging therapeutics for rheumatoid arthritis. Bull. NYU Hosp. Jt. Dis. 66: 210-215.
15. Buch, M. H., and P. Emery. 2011. New therapies in the management of rheumatoid arthritis. Curr. Opin. Rheumatol. 23: 245-251.
16. Walker, J. G., and M. D. Smith. 2005. The Jak-STAT pathway in rheumatoid arthritis. J. Rheumatol. 32: 1650-1653. (Pubitemid 41324798)
17. Shuai, K., and B. Liu. 2003. Regulation of JAK-STAT signalling in the immune system. Nat. Rev. Immunol. 3: 900-911. (Pubitemid 37411719)
18. Cohen, S., and R. Fleischmann. 2010. Kinase inhibitors: a new approach to rheumatoid arthritis treatment. Curr. Opin. Rheumatol. 22: 330-335.
19. Ghoreschi, K., A. Laurence, and J. J. O'Shea. 2009. Janus kinases in immune cell signaling. Immunol. Rev. 228: 273-287.
20. Paunovic, V., H. P. Carroll, K. Vandenbroeck, and M. Gadina. 2008. Signalling, inflammation and arthritis: crossed signals: the role of interleukin (IL)-12, -17, -23 and -27 in autoimmunity. Rheumatology (Oxford) 47: 771-776. (Pubitemid 351796359)
21. Sarma, U., and A. M. Flanagan. 1996. Macrophage colony-stimulating factor induces substantial osteoclast generation and bone resorption in human bone marrow cultures. Blood 88: 2531-2540. (Pubitemid 26327503)
22. Kawaji, H., K. Yokomura, K. Kikuchi, Y. Somoto, and Y. Shirai. 1995. [Macrophage colony-stimulating factor in patients with rheumatoid arthritis]. Nippon Ika Daigaku Zasshi 62: 260-270.
23. Tanaka, S., N. Takahashi, N. Udagawa, T. Tamura, T. Akatsu, E. R. Stanley, T. Kurokawa, and T. Suda. 1993. Macrophage colony-stimulating factor is indispensable for both proliferation and differentiation of osteoclast progenitors. J. Clin. Invest. 91: 257-263. (Pubitemid 23037280)
24. Paniagua, R. T., A. Chang, M. M. Mariano, E. A. Stein, Q. Wang, T. M. Lindstrom, O. Sharpe, C. Roscow, P. P. Ho, D. M. Lee, and W. H. Robinson. 2010. c-Fms-mediated differentiation and priming of monocyte lineage cells play a central role in autoimmune arthritis. Arthritis Res. Ther. 12: R32.
25. Conway, J. G., H. Pink, M. L. Bergquist, B. Han, S. Depee, S. Tadepalli, P. Lin, R. C. Crumrine, J. Binz, R. L. Clark, et al. 2008. Effects of the cFMS kinase inhibitor 5-(3-methoxy-4-((4-methoxybenzyl)oxy)benzyl)pyrimidine-2,4- diamine (GW2580) in normal and arthritic rats. J. Pharmacol. Exp. Ther. 326: 41-50. (Pubitemid 351872132)
26. Ohno, H., Y. Uemura, H. Murooka, H. Takanashi, T. Tokieda, Y. Ohzeki, K. Kubo, and I. Serizawa. 2008. The orally-active and selective c-Fms tyrosine kinase inhibitor Ki20227 inhibits disease progression in a collagen-induced arthritis mouse model. Eur. J. Immunol. 38: 283-291.
27. Karsunky, H., M. Merad, A. Cozzio, I. L.Weissman, and M. G. Manz. 2003. Flt3 ligand regulates dendritic cell development from Flt3+ lymphoid and myeloid-committed progenitors to Flt3+ dendritic cells in vivo. J. Exp. Med. 198: 305-313. (Pubitemid 36987855)
28. Dehlin, M., M. Bokarewa, R. Rottapel, S. J. Foster, M. Magnusson, L. E. Dahlberg, and A. Tarkowski. 2008. Intra-articular fms-like tyrosine kinase 3 ligand expression is a driving force in induction and progression of arthritis. PLoS ONE 3: e3633.
29. Lean, J. M., K. Fuller, and T. J. Chambers. 2001. FLT3 ligand can substitute for macrophage colony-stimulating factor in support of osteoclast differentiation and function. Blood 98: 2707-2713.
30. William, A. D., A. C. Lee, A. Poulsen, K. C. Goh, B. Madan, S. Hart, E. Tan, H. Wang, H. Nagaraj, D. Chen, et al. 2012. Discovery of the macrocycle (9E)-15-(2-(pyrrolidin-1-yl)ethoxy)-7,12,25-trioxa-19,21,24-triaza-tetracyclo [18.3.1.1(2,5).1(14,18)]hexacosa-1(24),2,4,9,14(26),15,17,20,22-nonaene (SB1578), a potent inhibitor of janus kinase 2/fms-like tyrosine kinase-3 (JAK2/FLT3) for the treatment of rheumatoid arthritis. J. Med. Chem. 55: 2623-2640.
31. Hart, S., K. C. Goh, V. Novotny-Diermayr, C. Y. Hu, H. Hentze, Y. C. Tan, B. Madan, C. Amalini, Y. K. Loh, L. C. Ong, et al. 2011. SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies. Leukemia 25: 1751-1759.
32. Watford, W. T., B. D. Hissong, J. H. Bream, Y. Kanno, L. Muul, and J. J. O'Shea. 2004. Signaling by IL-12 and IL-23 and the immunoregulatory roles of STAT4. Immunol. Rev. 202: 139-156. (Pubitemid 39576910)
33. Fantuzzi, L., P. Borghi, V. Ciolli, G. Pavlakis, F. Belardelli, and S. Gessani. 1999. Loss of CCR2 expression and functional response to monocyte chemotactic protein (MCP-1) during the differentiation of human monocytes: role of secreted MCP-1 in the regulation of the chemotactic response. Blood 94: 875-883. (Pubitemid 29361817)
34. Kreutz, M., J. Fritsche, U. Ackermann, S. W. Krause, and R. Andreesen. 1998. Retinoic acid inhibits monocyte to macrophage survival and differentiation. Blood 91: 4796-4802. (Pubitemid 28270331)
35. Benslay, D. N., and A. M. Bendele. 1991. Development of a rapid screen for detecting and differentiating immunomodulatory vs. anti-inflammatory compounds in rats. Agents Actions 34: 254-256.
36. Haringman, J. J., D. M. Gerlag, A. H. Zwinderman, T. J. Smeets, M. C. Kraan, D. Baeten, I. B. McInnes, B. Bresnihan, and P. P. Tak. 2005. Synovial tissue macrophages: a sensitive biomarker for response to treatment in patients with rheumatoid arthritis. Ann. Rheum. Dis. 64: 834-838. (Pubitemid 40733904)
37. Cascão, R., H. S. Rosário, M. M. Souto-Carneiro, and J. E. Fonseca. 2010. Neutrophils in rheumatoid arthritis: more than simple final effectors. Autoimmun. Rev. 9: 531-535.
38. Wipke, B. T., and P. M. Allen. 2001. Essential role of neutrophils in the initiation and progression of a murine model of rheumatoid arthritis. J. Immunol. 167: 1601-1608. (Pubitemid 32703161)
39. Opar, A. 2010. Kinase inhibitors attract attention as oral rheumatoid arthritis drugs. Nat. Rev. Drug Discov. 9: 257-258.
40. Pesu, M., A. Laurence, N. Kishore, S. H. Zwillich, G. Chan, and J. J. O'Shea. 2008. Therapeutic targeting of Janus kinases. Immunol. Rev. 223: 132-142. (Pubitemid 351986189)
41. Houssiau, F. A., J. P. Devogelaer, J. Van Damme, C. N. de Deuxchaisnes, and J. Van Snick. 1988. Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides. Arthritis Rheum. 31: 784-788.
42. Mertens, M., and J. A. Singh. 2009. Anakinra for rheumatoid arthritis: a systematic review. J. Rheumatol. 36: 1118-1125.
43. Weiss, S. J. 1989. Tissue destruction by neutrophils. N. Engl. J. Med. 320: 365-376. (Pubitemid 19106873)
44. Kagari, T., D. Tanaka, H. Doi, Y. Iwakura, and T. Shimozato. 2007. Anti-type II collagen antibody accelerates arthritis via CXCR2-expressing cells in IL-1 receptor antagonist-deficient mice. Eur. J. Immunol. 37: 2753-2763. (Pubitemid 47578294)
45. Fridman, J. S., P. A. Scherle, R. Collins, T. C. Burn, Y. Li, J. Li, M. B. Covington, B. Thomas, P. Collier, M. F. Favata, et al. 2010. Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050. J. Immunol. 184: 5298-5307.
46. Stump, K. L., L. D. Lu, P. Dobrzanski, C. Serdikoff, D. E. Gingrich, B. J. Dugan, T. S. Angeles, M. S. Albom, M. A. Ator, B. D. Dorsey, et al. 2011. A highly selective, orally active inhibitor of Janus kinase 2, CEP-33779, ablates disease in two mouse models of rheumatoid arthritis. Arthritis Res. Ther. 13: R68.
47. Joosten, L. A., E. Lubberts, M. M. Helsen, and W. B. van den Berg. 1997. Dual role of IL-12 in early and late stages of murine collagen type II arthritis. J. Immunol. 159: 4094-4102. (Pubitemid 127469668)
48. Whartenby, K. A., P. A. Calabresi, E. McCadden, B. Nguyen, D. Kardian, T. Wang, C. Mosse, D. M. Pardoll, and D. Small. 2005. Inhibition of FLT3 signaling targets DCs to ameliorate autoimmune disease. Proc. Natl. Acad. Sci. USA 102: 16741-16746. (Pubitemid 41688847)
49. Thomas, R., K. P. MacDonald, A. R. Pettit, L. L. Cavanagh, J. Padmanabha, and S. Zehntner. 1999. Dendritic cells and the pathogenesis of rheumatoid arthritis. J. Leukoc. Biol. 66: 286-292. (Pubitemid 29379170)
50. Dehlin, M., S. Andersson, M. Erlandsson, M. Brisslert, and M. Bokarewa. 2011. Inhibition of fms-like tyrosine kinase 3 alleviates experimental arthritis by reducing formation of dendritic cells and antigen presentation. J. Leukoc. Biol. 90: 811-817.
51. Bartok, B., and G. S. Firestein. 2010. Fibroblast-like synoviocytes: key effector cells in rheumatoid arthritis. Immunol. Rev. 233: 233-255.
52. Singh, J. A., G. A. Wells, R. Christensen, E. Tanjong Ghogomu, L. Maxwell, J. K. Macdonald, G. Filippini, N. Skoetz, D. Francis, L. C. Lopes, et al. 2011. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst. Rev. (2):CD008794.
53. Riese, R. J., S. Krishnaswami, and J. Kremer. 2010. Inhibition of JAK kinases in patients with rheumatoid arthritis: scientific rationale and clinical outcomes. Best Pract. Res. Clin. Rheumatol. 24: 513-526.
54. Milici, A. J., E. M. Kudlacz, L. Audoly, S. Zwillich, and P. Changelian. 2008. Cartilage preservation by inhibition of Janus kinase 3 in two rodent models of rheumatoid arthritis. Arthritis Res. Ther. 10: R14.